FDA Panel Endorses Donanemab to Treat Early-Stage Alzheimer Disease

Donanemab was able to significantly slow clinical progression of Alzheimer disease and amyloid and tau pathology at 76 weeks of treatment.

Related Keywords

California ,United States ,Myra Garcia ,Eli Lilly ,Anne White ,Howard Fillit ,Drug Administration To Convene Advisory Committee Meeting ,Alzheimer Association ,Alzheimer Drug Discovery Foundation ,Central Nervous System Drugs Advisory Committee ,Cnn ,Chief Science Officer ,Drug Discovery Foundation ,Drug Discovery ,Drug Administration ,Convene Advisory Committee Meeting ,Early Symptomatic Alzheimer ,